Logo
Logo

About Gatifloxacin (Anhydrous) API

Product
  • Therapeutic CategoryAnti-Infective

  • CAS Number

    112811-59-3

  • API Technology

    Synthetic

  • Dose Form

    Opthalmic

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    Brazil DMF, USDMF

Mechanism of Action

Gatifloxacin is a quinolone antimicrobial drug

Gatifloxacin is an 8-methoxyfluoroquinolone with a 3-methylpiperazinyl substituent at C7. The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.

Indication

ZYMAR® is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:

Haemophilus influenzae, Corynebacterium propinquum, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group, Streptococcus pneumoniae

Related APIs

Ciprofloxacin Hydrochloride

Anti-Infective

arrow

Gatifloxacin (Anhydrous)

Anti-Infective

arrow

Levofloxacin Hemihydrate

Anti-Infective

arrow

Moxifloxacin Hydrochloride (Anhydrous)

Anti-Infective

arrow

Permethrin

Anti-Infective

arrow

Posaconazole

Anti-Infective

arrow

Terbinafine Hydrochloride

Anti-Infective

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.